RxDoctor Payments Data

Warren Gude, MD

Undersea and Hyperbaric Medicine · Boise, IDNPI 1255399820

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations.

$4,102in general payments, 2019–2025

Across 67 payments — averaging $61.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mimedx Group, Inc.$572
  • Acera Surgical, Inc.$530
  • Reapplix Inc.$454
  • Kerecis Limited$441
  • Smith+Nephew$354
  • KCI USA, Inc.$274
  • plus $1K from 16 others
$4,500in research payments, 2019–2025

Across 3 payments — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Reapplix Inc.$5K

What the payments were for

  • Food & beverage$4,102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few undersea and hyperbaric medicine providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$76,549
Medicare patients
303
Services billed
1,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate71$1,909
Pentoxifylline32$1,278
Gentamicin Sulfate17$712
Doxycycline Monohydrate11$484
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav31$454
Clindamycin Hcl11$333
Ciprofloxacin Hcl35$320
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip15$240
Mupirocin15$131

Paid to pharmacies, not to this prescriber.

Other undersea and hyperbaric medicine in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →